Supplemental Material

- 1 Low uveitis rates in patients with axial spondyloarthritis
- 2 treated with bimekizumab: pooled results from phase

3 **2b/3 trials**


- 4
- 5 <u>Matthew A. Brown</u>,^{1,2*} Martin Rudwaleit,^{3*} Floris A. van Gaalen,⁴ Nigil
- 6 Haroon,⁵ Lianne S. Gensler,⁶ Carmen Fleurinck,⁷ Alexander Marten,⁸ Ute
- 7 Massow,⁸ Natasha de Peyrecave,⁷ Thomas Vaux,⁹ Katy White,⁹ Atul
- 8 Deodhar,¹⁰ Irene E. van der Horst-Bruinsma¹¹
- 9
- 10 *MAB and MR are joint first authors and contributed equally.
- 11 ¹Genomics England, London, UK; ²Department of Medical and Molecular Genetics,
- 12 Faculty of Life Sciences and Medicine, King's College London, London, UK;
- 13 ³University of Bielefeld, Klinikum Bielefeld, Bielefeld, Germany; ⁴Leiden University
- 14 Medical Center, Department of Rheumatology, Leiden, The Netherlands; ⁵University
- 15 of Toronto, University Health Network, Schroeder Arthritis Institute, Department of
- 16 Medicine/Rheumatology, Toronto, Ontario, Canada; ⁶University of California, San
- 17 Francisco, Department of Medicine/Rheumatology, San Francisco, California, USA;
- 18 ⁷UCB Pharma, Brussels, Belgium; ⁸UCB Pharma, Monheim am Rhein, Germany; ⁹UCB
- 19 Pharma, Slough, UK; ¹⁰Oregon Health & Science University, Division of Arthritis &
- 20 Rheumatic Diseases, Portland, Oregon, USA; ¹¹Radboud University Medical Centre,
- 21 Department of Rheumatology, Nijmegen, The Netherlands
- 22 Correspondence to: Matthew A. Brown (Genomics England, London, UK;
- 23 matt.brown@genomicsengland.co.uk)

Supplemental Material

1 SUPPLEMENTARY DATA

2 Figure S1. Pooling of data from the phase 3 BE MOBILE 1 and 2 and phase

3 **2 BE AGILE trials**



⁵ ^aTrial ongoing. BKZ: bimekizumab; DBTP: double-blind treatment period; nr-axSpA: non-radiographic

6 axial spondyloarthritis; OLE: open-label extension; PYs: patient-years; Q4W: every four weeks; r-axSpA:

7 radiographic axial spondyloarthritis.

4